Thomas A. D’Amico, MD, of the Duke Comprehensive Cancer Center, is the new chairman of the NCCN Board of Directors succeeding Al B. Benson III, MD, of Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
April 1, 2010
FORT WASHINGTON, PA — Thomas A. D’Amico, MD, of the Duke Comprehensive Cancer Center has been elected to the position of chairman of the National Comprehensive Cancer Network® (NCCN®) Board of Directors. Dr. D’Amico was previously vice-chairman of the board and succeeds Al B. Benson III, MD. The change in leadership was formalized at a recent NCCN Board of Directors meeting held in conjunction with the NCCN 15th Annual Conference.
"I thank Dr. Benson for his vision, leadership and inspiration. He's been an outstanding chairman of the board," said William T. McGivney, PhD, chief executive officer of NCCN. "I'm confident Dr. D’Amico will be an excellent successor. He's been a devoted, enthusiastic friend of NCCN for many years and I look forward to working with him in his new leadership role."
Dr. D’Amico is director of clinical oncology, program director of thoracic surgery, and professor in the department of surgery at Duke Comprehensive Cancer Center. He is a recognized leader in the field of oncology with interests including lung cancer, esophageal cancer, and thoracic surgery. Dr. D’Amico remains active in the research community with a focus on the molecular biology of lung cancer and esophageal cancer and the genomic analysis of mutations. He is a member of several NCCN committees and serves on the NCCN Guidelines™ Panels for Esophageal/Gastric Cancers and for Non-Small Cell Lung Cancer.
“I am honored to be chosen for this prestigious position,” said Dr. D’Amico. “Given the wealth of ideas and spirit of the members who comprise the board, there is no doubt in my mind that we can continue to make an outstanding organization such as NCCN even better.”
Dr. Benson, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University was chairman of the board since 2007. A committed member of several NCCN committees and NCCN Guidelines Panels, Dr. Benson will remain a member of the board.
Succeeding Dr. D’Amico as vice-chairman of the NCCN Board of Directors is Samuel M. Silver, MD, PhD, of the University of Michigan Comprehensive Cancer Center.
The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 23 of the world's leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives. For more information, visit NCCN.org.